Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Welcome to Abbott's third quarter 2024 earnings conference call. [Operator instructions] This call is being recorded by Abbott. With the exception of any participants questions asked during the question-and-answer session,
Abbott Laboratories posts Q3 beat, raises profit forecast
Abbott Laboratories (ABT) shares tick into positive territory in Wednesday's pre-market trading on its third quarter earnings beat driven by strong demand for the company's medical devices. Morning Brief Hosts Seana Smith and Brad Smith break down what investors need to know.
Abbott Laboratories Q3 Profit Increases, Beats Estimates
Abbott Laboratories (ABT) revealed earnings for its third quarter that increased from the same period last year and beat the Street
Abbott: Q3 Earnings Snapshot
On a per-share basis, the Abbott Park, Illinois-based company said it had profit of 94 cents. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $1.20 per share.
Abbott Labs beats Q3 sales and earnings expectations, raises full-year outlook
Abbott Laboratories on Wednesday reported better-than-expected third-quarter earnings and sales, boosted by strength in the company’s medical-devices business.
Abbott Stock Gains on Q3 Earnings Beat, Margins Expand
Abbott Laboratories ABT reported third-quarter 2024 adjusted earnings per share (EPS) of $1.21, which beat the Zacks Consensus Estimate by 0.8%. The figure also improved 6.1% from the prior-year quarter’s level.
ABT Earnings: Strong Medical Device Sales Help Abbott Beat Q3 Estimates
Abbott ($ABT) reported better-than-expected third-quarter results on Wednesday. The medical devices and healthcare company’s sales increased by
Abbott Laboratories Narrows Full-Year Earnings Outlook Range Following Third-Quarter Beat
Abbott Laboratories (ABT) reported better-than-expected third-quarter results on Wednesday amid double-digit revenue growth in its medical devices segment, while the healthcare company narrowed its full-year earnings outlook range.
Abbott raises earnings outlook as MedTech, Pharma drive Q3 beat
Abbott Laboratories (NYSE:ABT) increased its full-year earnings guidance on Tuesday after its financials for Q3 2024 exceeded Wall Street's forecasts, thanks mainly to the strength in its Pharma and MedTech segments.
Benzinga.com2d
Abbott Laboratories' Q3 Earnings: Revenue And EPS Beat, Company Says Well-Positioned To Achieve Upper End Of Annual Forecast
Abbott's Q3 sales reached $10.64B, beating the consensus of $10.55B ... beating the analyst estimates of $1.20. Also Read ...
Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Abbott Laboratories' Q3 earnings and topline growth largely expected to be in line with the Q2 trend. Find out whether ABT ...
High-Quality Abbott Stock: Corporate Growth That Pays You to Own It
Abbott Laboratories is the #1 healthcare stock to own for consistent, market-beating returns over the long term. Q3 results ...
Travis Steed Reiterates Buy Rating on Abbott Laboratories Amid Promising Growth and Under-Ownership Potential
Travis Steed, an analyst from Bank of America Securities, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The ...
Abbott Laboratories: It's No Longer A Buy For Now
Abbott Laboratories is showing strong growth potential with rising sales and EPS, though slightly overvalued. See why we are ...
The Motley Fool11d
Best Medical Device Stocks to Buy for 2024
Top medical device stocks include Abbott Laboratories and GE Healthcare. Investment options also include medical device ETFs such as the iShares U.S. Medical Devices ETF. Key findings are powered ...
pharmaphorum1d
A history of Abbott and AbbVie
This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...